Abstract
Amyloid-imaging agents such as 18F-florbetapir, 18F-flutemetamol, and 18F-florbetaben diffuse across the blood–brain barrier, are taken up in the neuritic plaques, and produce a radioactive signal that is detectable throughout the brain. The highest level of amyloid tracers uptake in the normal brain mostly regards white matter; in the body, they are enhanced in salivary glands, liver, muscles, and bone marrow.
The uptake of amyloid tracers in the gray matter is linked to the deposition of amyloid. Therefore, these tracers are useful for PET and PET/CT imaging of amyloid-related kinds of dementia. In particular, PET with amyloid tracers is useful in evaluating patients with mild cognitive impairment and Alzheimer’s disease. Future studies are needed to clarify the potential added value of these radiopharmaceuticals in evaluation of systemic or cardiac amyloidosis.
Diagnostic pitfalls can be due to rapid washout of tracers in the brain, faint uptake in vascular dementia, or motion artifacts in PET/CT fusion imaging.
This is a preview of subscription content, log in via an institution.
Buying options
Tax calculation will be finalised at checkout
Purchases are for personal use only
Learn about institutional subscriptionsAbbreviations
- 18F-FDG:
-
18F-Fluorodeoxyglucose
- AD:
-
Alzheimer’s disease
- MCI:
-
Mild cognitive impairment
- PET/CT:
-
Positron emission tomography/computed tomography
- SUVR :
-
Standardized uptake value ratio
References
Mason NS, Mathis CA, Klunk WE. Positron emission tomography radioligands for in vivo imaging of Aβ plaques. J Labelled Comp Radiopharm. 2013;56:89–95.
Hang W, Oya S, Kung MP, et al. F-18 polyethyleneglycol stilbenes as PET imaging agents targeting Abeta aggregates in the brain. Nucl Med Biol. 2005;32:799–809.
Wang H, Guo X, Jiang S, et al. Automated synthesis of [18F]Florbetaben as Alzheimer’s disease imaging agent based on a synthesis module system. Appl Radiat Isot. 2013;71:461–46.
Hardy JA, Higgins GA. Alzheimer’s disease: the amyloid cascade hypothesis. Science. 1992;10:184–5.
Priller C, Bauer T, Mitteregger G, et al. Synapse formation and function is modulated by the amyloid precursor protein. J Neurosci. 2006;5:7212–21.
Saint-Aubert L, Lemoine L, Chiotis K, Leuzy A, et al. Tau PET imaging: present and future directions. Mol Neurodegener. 2017;20:19.
Trembath L, Newell M, Devous MD Sr. Technical considerations in brain amyloid PET imaging with 18F-florbetapir. J Nucl Med Technol. 2015;43:15–184.
Thal DR, Beach TG, Zanette M, et al. Estimation of amyloid distribution by [18F]flutemetamol PET predicts the neuropathological phase of amyloid β-protein deposition. Acta Neuropathol. 2018;136:557–67.
Petersen RC, Waring SC, Smith GE, et al. Predictive value of APOE genotyping in incipient Alzheimer’s disease. Ann New York Acad Sci. 1996;802:58–69.
Ong K, Villemagne VL, Bahar-Fuchs A, et al. (18)F-florbetaben Abeta imaging in mild cognitive impairment. Alzheimers Res Ther. 2013;5:4.
Ong KT, Villemagne VL, Bahar-Fuchs A, et al. Abeta imaging with 18F-florbetaben in prodromal Alzheimer’s disease: a prospective outcome study. J Neurol Neurosurg Psychiatry. 2015;86:431–6.
Martínez G, Vernooij RW, Fuentes Padilla P, et al. 18F PET with flutemetamol for the early diagnosis of Alzheimer’s disease dementia and other dementias in people with mild cognitive impairment (MCI). Cochrane Database Syst Rev. 2017;(22):CD012884.
Barthel H, Sabri O. Florbetaben to trace amyloid-beta in the Alzheimer brain by means of PET. J Alzheimers Dis. 2011;26:117–21.
Becker GA, Ichise M, Barthel H, et al. PET quantification of 18F-florbetaben binding to beta-amyloid deposits in human brains. J Nucl Med. 2013;54:723–31.
Barthel H, Gertz HJ, Dresel S, et al. Cerebral amyloid-beta PET with florbetaben (18F) in patients with Alzheimer’s disease and healthy controls: a multicentre phase 2 diagnostic study. Lancet Neurol. 2011;10:424–35.
Sabri O, Sabbagh MN, Seibyl J, et al. Florbetaben PET imaging to detect amyloid beta plaques in Alzheimer disease: phase 3 study. Alzheimers Dement. 2015;28:00060–6.
Perani D, Schillaci O, Padovani A, et al. A survey of FDG- and amyloid-PET imaging in dementia and GRADE analysis. Biomed Res Int. 2014;2014:785039.
Rowe CC, Ackerman U, Browne W, et al. Imaging of amyloid beta in Alzheimer’s disease with 18F-BAY94-9172, a novel PET tracer: proof of mechanism. Lancet Neurol. 2008;7:129–35.
Newberg AB, Arnold SE, Wintering N, et al. Initial clinical comparison of 18F-florbetapir and 18F-FDG PET in patients with Alzheimer disease and controls. J Nucl Med. 2012;53:902–7.
Barthel H, Gertz HJ, Dresel S, et al. Cerebral amyloid-β PET with florbetaben (18F) in patients with Alzheimer’s disease and healthy controls: a multicentre phase 2 diagnostic study. Lancet Neurol. 2011;10:424–5.
Tiepolt S, Barthel H, Butzke D, et al. Influence of scan duration on the accuracy of β-amyloid PET with florbetaben in patients with Alzheimer’s disease and healthy volunteers. Eur J Nucl Med Mol Imaging. 2013;40:238–44.
Arai A, Kaneta T, Okamura N, et al. Pitfalls of voxel-based amyloid PET analyses for diagnosis of Alzheimer’s disease: artifacts due to non-specific uptake in the white matter and the skull. Tohoku J Exp Med. 2014;234:175–81.
Pelletier-Galarneau M, Abikhzer G, Giraldeau G, et al. Molecular imaging of cardiac amyloidosis. Curr Cardiol Rep. 2019;28:12.
Manwani R, Page J, Lane T, et al. A pilot study demonstrating cardiac uptake with 18F-florbetapir PET in AL amyloidosis patients with cardiac involvement. Amyloid. 2018;25:247–52.
Townley RA, Botha H, Graff-Radford J, et al. 18F-FDG PET-CT pattern in idiopathic normal pressure hydrocephalus. Neuroimage Clin. 2018;28:897–902.
Rinne JO, Suotunen T, Rummukainen J, et al. [11C]PIB PET is associated with the brain biopsy amyloid-β load in subjects examined for Normal pressure hydrocephalus. J Alzheimers Dis. 2019;67:1343–51.
Jang H, Park SB, Kim Y, et al. Prognostic value of amyloid PET scan in normal pressure hydrocephalus. J Neurol. 2018;265:63–73.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2020 Springer Nature Switzerland AG
About this chapter
Cite this chapter
Chiaravalloti, A., Calabria, F., Bagnato, A., Schillaci, O. (2020). Amyloid Imaging. In: Calabria, F., Schillaci, O. (eds) Radiopharmaceuticals. Springer, Cham. https://doi.org/10.1007/978-3-030-27779-6_8
Download citation
DOI: https://doi.org/10.1007/978-3-030-27779-6_8
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-030-27778-9
Online ISBN: 978-3-030-27779-6
eBook Packages: MedicineMedicine (R0)